Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study
Open Access
- 1 February 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 14 (2), 479-484
- https://doi.org/10.1093/humrep/14.2.479
Abstract
Endometrial hyperplasia is thought to be caused by the prolonged, unopposed oestrogenic stimulation of the endometrium. The regression of hyperplastic back to normal endometrium is the main purpose of any conservative treatment in order to prevent development of adenocarcinoma. The aim of this study was to evaluate the regression of hyperplastic to normal endometrium in patients with various forms of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue (GnRHa) triptorelin for 6 months. Fifty-six patients with endometrial hyperplasia were enrolled in this trial; 39 patients (group I) presented simple hyperplasia, 14 (group II) complex hyperplasia and three (group III) atypical complex hyperplasia. All patients were treated with triptorelin for 6 months. Bleeding control during treatment was excellent. A post-treatment curettage for estimation of endometrial histology was performed on 54 out of 56 patients 100.1 ± 44.7 days after the last triptorelin dose, following the restoration of pituitary function. Regression of hyperplastic to normal endometrium was observed in 32 (86.5%) out of 37 patients in group I and in 12 (85.7%) out of 14 in group II. Persistence of simple hyperplasia was found in five (14.5%) out of 37 patients in group I. Persistence of complex hyperplasia was found in 1 (7.1%) out of 14 patients and progression to atypical complex hyperplasia in another one (7.1%) woman in group II. In some of these cases, the presence of risk factors such as obesity, diabetes mellitus and ovulatory disturbances may contribute to the disease persistence despite therapy. On the other hand, in group III, none of the three patients had normal post-treatment endometrial histology. It seems, therefore, that in cases of endometrial hyperplasia without atypia, the administration of the GnRHa triptorelin is associated with high regression rates to normal endometrium. Conversely, the presence of atypia seems to be a poor prognostic factor. Treatment tolerance and bleeding control during therapy is excellent.Keywords
This publication has 22 references indexed in Scilit:
- Treatment of Endometrial Hyperplasias with Gonadotropin-Releasing Hormone Agonists: Pathological, Clinical, Morphometric, and DNA-Cytometric DataGynecologic Oncology, 1997
- Endometrial hyperplasia: Efficacy of a new treatment with a vaginal cream containing natural micronized progesteroneMaturitas, 1994
- Increased expression of luteinizing hormone/human chorionic gonadotropin receptor gene in human endometrial carcinomasJournal of Clinical Endocrinology & Metabolism, 1994
- Clinical Response of Abnormal Endometrial Growth to Hormonal TreatmentAnnals of the New York Academy of Sciences, 1994
- Immunohistochemical Detection of the c-myc Oncogene Product in Normal, Hyperplastic and Carcinomatous EndometriumOncology, 1994
- High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell linesJournal of Clinical Endocrinology & Metabolism, 1993
- The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrial and myometrial blood vesselsJournal of Clinical Endocrinology & Metabolism, 1992
- Treatment of Endometrial Cancer with GnRH AnalogsPublished by Springer Nature ,1992
- An intrauterine progesterone contraceptive system (52 mg) used in pre- and peri-menopausal patients with endometrial hyperplasiaMaturitas, 1982
- Progestin therapy in endometrial hyperplasiaGynecologic Oncology, 1974